Patterns and Predictors of Psychiatric Polypharmacy and Fixed-Dose Combination Use: A Cross-Sectional Study from a Tertiary Care Hospital in Eastern India

Psychiatric polypharmacy and fixed-dose combination (FDC) prescribing are frequently observed in tertiary care psychiatry. While appropriate in selected scenarios such as treatment-resistant illness or comorbidities, both practices carry risks of adverse drug reactions, drug–drug interactions, and poor adherence. To determine the prevalence, patterns, and predictors of psychiatric polypharmacy and FDC use among psychiatric outpatients in a tertiary care hospital in Eastern India. A three-month cross-sectional study was conducted in the Psychiatry Outpatient Department of a government tertiary hospital. Prescriptions containing at least one psychotropic drug were obtained by convenience sampling. Socio-demographic, clinical, and prescribing details were recorded using a structured form. Psychiatric polypharmacy was defined as ≥2 psychotropics per prescription; general polypharmacy as ≥5 drugs. Associations were tested using chi-square and logistic regression. Among 150 prescriptions, psychiatric polypharmacy was present in 67.3%, general polypharmacy in 41.3%, and FDC use in 41.3%. Psychotropic FDCs accounted for 22.7% of prescriptions. Polypharmacy was significantly associated with age (p=0.048), socio-economic status (p=0.032), and diagnosis (p=0.001). Logistic regression confirmed schizophrenia spectrum disorders (OR=2.91, 95% CI: 1.24–6.83) and middle socio-economic status (OR=2.37, 95% CI: 1.02–5.49) as independent predictors. High rates of psychiatric polypharmacy and FDC use, particularly in schizophrenia, highlight the need for regular prescription audits, prescriber education, and stricter regulation of irrational FDCs. Limitations include convenience sampling, modest sample size, and single-centre design. Multicentric, longitudinal studies are needed to evaluate outcomes and guide rational psychotropic prescribing. Keywords: Psychiatry, Polypharmacy, Fixed-dose combinations, Psychotropic drugs, Prescription audit, Rational prescribing

Authors

Publication Details

Journal
Journal of Pharmaceutical Research
Published
2025-12-20
DOI
https://doi.org/10.18579/jopcr/v24.i4.132
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patterns and Predictors of Psychiatric Polypharmacy and Fixed-Dose Combination Use: A Cross-Sectional Study from a Tertiary Care Hospital in Eastern India

Payeli Debbarma, SK Sabir Rahaman, Ruma Mandal
Journal of Pharmaceutical Research
Pharmaceutical Practices and Patient Outcomes
article

Patterns and Predictors of Psychiatric Polypharmacy and Fixed-Dose Combination Use: A Cross-Sectional Study from a Tertiary Care Hospital in Eastern India

Payeli Debbarma, SK Sabir Rahaman, Ruma Mandal
article en

Abstract

Psychiatric polypharmacy and fixed-dose combination (FDC) prescribing are frequently observed in tertiary care psychiatry. While appropriate in selected scenarios such as treatment-resistant illness or comorbidities, both practices carry risks of adverse drug reactions, drug–drug interactions, and poor adherence. To determine the prevalence, patterns, and predictors of psychiatric polypharmacy and FDC use among psychiatric outpatients in a tertiary care hospital in Eastern India. A three-month cross-sectional study was conducted in the Psychiatry Outpatient Department of a government tertiary hospital. Prescriptions containing at least one psychotropic drug were obtained by convenience sampling. Socio-demographic, clinical, and prescribing details were recorded using a structured form. Psychiatric polypharmacy was defined as ≥2 psychotropics per prescription; general polypharmacy as ≥5 drugs. Associations were tested using chi-square and logistic regression. Among 150 prescriptions, psychiatric polypharmacy was present in 67.3%, general polypharmacy in 41.3%, and FDC use in 41.3%. Psychotropic FDCs accounted for 22.7% of prescriptions. Polypharmacy was significantly associated with age (p=0.048), socio-economic status (p=0.032), and diagnosis (p=0.001). Logistic regression confirmed schizophrenia spectrum disorders (OR=2.91, 95% CI: 1.24–6.83) and middle socio-economic status (OR=2.37, 95% CI: 1.02–5.49) as independent predictors. High rates of psychiatric polypharmacy and FDC use, particularly in schizophrenia, highlight the need for regular prescription audits, prescriber education, and stricter regulation of irrational FDCs. Limitations include convenience sampling, modest sample size, and single-centre design. Multicentric, longitudinal studies are needed to evaluate outcomes and guide rational psychotropic prescribing. Keywords: Psychiatry, Polypharmacy, Fixed-dose combinations, Psychotropic drugs, Prescription audit, Rational prescribing

Journal of Pharmaceutical ResearchVol. 24(4)
No poverty
Openalex Percentile: Top 29%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.